FDA's $6.4 Billion Plan for Quick Reviews Moves to Senate
In this overview of the user fee legislation making its way through Congress, Catalyst's Ms. Myers comments on the new FDA review model for NMEs and novel biologics. "Drug developers feel there really is value in getting FDA's perspective early to avoid surprises in an application review," she says in the article. She is also